1
|
McWilliam A, Kerns S, Marshall D, Azria D, Farcy-Jacquet M, Chang-Claude J, Choudhury A, Dunning A, Lambrecht M, Avuzzi B, de Ruysscher D, Seibold P, Sperk E, Talbot C, Vega A, Veldeman L, Webb A, Rancati T, Rosenstein B, West C. Prostate Cancer Patients with a High Polygenic Risk of Rheumatoid Arthritis have Increased Radiotherapy Toxicity. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Cooke S, de Ruysscher D, Reymen B, Lambrecht M, Persson GF, Faivre-Finn C, Dieleman E, van Diessen J, Damen E, Sikorska K, Belderbos J, Sonke J. Whole Tumor vs. FDG-Directed Dose Escalation in Patients with Locally Advanced NSCLC: Evaluation of Isotoxic Treatment Plans from the Randomized ARTFORCE PET-Boost Trial. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
De Roeck L, Spiessens P, Vermeulen H, Clement P, Daisne J, De Vleeschouwer S, Sleurs C, Lambrecht M. P01.09.A Prevalence and predictors of cognitive impairment in adult glioma survivors after multimodal therapy. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Long-term survival can be achieved in an increasing number of glioma patients after treatment. Therefore, safeguarding these survivors’ quality of life (QoL) is essential. Neurocognitive decline arises in many young patients, placing a heavy burden on the social and economic aspects of the patients’ lives. A lot of debate is currently ongoing regarding the prevalence of neurocognitive impairment and individual predictors of whom is susceptible for such side effect.
Material and Methods
In this cross-sectional study, 37 WHO grade 2-3 adult glioma survivors, at least one year after multimodal therapy, were tested using a comprehensive neurocognitive test battery covering multiple cognitive domains. Neurocognitive test scores were converted into z-scores using country-specific normative data. Cognitive impairment was defined as a z-score lower or equal to -1.50 for each subtest. Age, time since multimodal therapy, radiotherapy treatment and tumour location were included as predictors in a linear regression model per outcome (n=12).
Results
In this cohort, 29 patients (78%) showed a test score below the predefined cutoff on at least one cognitive test. The percentage of patients who showed test-specific cognitive impairment ranged from 8.1% to 56.76% per test. Fine motor skills, verbal memory, processing speed and executive functioning were the most commonly affected cognitive domains. In this study, the variability in processing speed performance was associated with age (TMT A, p=0.03), time since therapy (WAIS-IV coding, p=0.02) and tumour location. In these measures, poorer outcomes were observed with increasing age, longer time since therapy and in patients with gliomas located in the left frontal lobe. Moreover, age showed to be a significant predictor of verbal memory, with poorer outcomes on the HVLT-R delayed recall task with increasing age (p=0.04). Tumour location predicted working memory performance, as patients with right parietal tumours (p=0.03) showed significantly worse on the WAIS-IV digit span task.
Conclusion
These preliminary data underline the various alterations of neurocognitive functioning in glioma survivors after multimodal therapy. Therefore, future research needs to shift towards a patient-tailored approach. The next step in this study will be to link these neurocognitive data to advanced neuroimaging data to explore the potential predictive value of imaging markers for neural damage and cognitive outcomes, paving the path to innovative treatment planning techniques.
Collapse
Affiliation(s)
- L De Roeck
- Department of Radiation Oncology, University Hospitals Leuven , Leuven , Belgium
- Laboratory of Experimental Radiotherapy, KU Leuven , Leuven , Belgium
| | - P Spiessens
- Department of Psychology, KU Leuven , Leuven , Belgium
| | - H Vermeulen
- Department of Psychology, KU Leuven , Leuven , Belgium
| | - P Clement
- Department of Oncology, University Hospitals Leuven , Leuven , Belgium
- Department of Oncology, KU Leuven , Leuven , Belgium
| | - J Daisne
- Department of Radiation Oncology, University Hospitals Leuven , Leuven , Belgium
- Laboratory of Experimental Radiotherapy, KU Leuven , Leuven , Belgium
| | - S De Vleeschouwer
- Department of Neurosurgery, University Hospitals Leuven , Leuven , Belgium
- Leuven Brain Institute, KU Leuven , Leuven , Belgium
| | - C Sleurs
- Department of Oncology, KU Leuven , Leuven , Belgium
- Leuven Brain Institute, KU Leuven , Leuven , Belgium
| | - M Lambrecht
- Department of Radiation Oncology, University Hospitals Leuven , Leuven , Belgium
- Laboratory of Experimental Radiotherapy, KU Leuven , Leuven , Belgium
| |
Collapse
|
4
|
Siltari A, Lönnerbro R, Pang K, Shiranov K, Asiimwe A, Evans-Axelsson S, Franks B, Kiran A, Murtola TJ, Schalken J, Steinbeisser C, Bjartell A, Auvinen A, Smith E, N'Dow J, Plass K, Ribal M, Mottet N, Moris L, Lardas M, Van den Broeck T, Willemse PP, Gandaglia G, Campi R, Greco I, Gacci M, Serni S, Briganti A, Crosti D, Meoni M, Garzonio R, Bangma R, Roobol M, Remmers S, Tilki D, Visakorpi T, Talala K, Tammela T, van Hemelrijck M, Bayer K, Lejeune S, Taxiarchopoulou G, van Diggelen F, Senthilkumar K, Schutte S, Byrne S, Fialho L, Cardone A, Gono P, De Vetter M, Ceke K, De Meulder B, Auffray C, Balaur IA, Taibi N, Power S, Kermani NZ, van Bochove K, Cavelaars M, Moinat M, Voss E, Bernini C, Horgan D, Fullwood L, Holtorf M, Lancet D, Bernstein G, Omar I, MacLennan S, Maclennan S, Healey J, Huber J, Wirth M, Froehner M, Brenner B, Borkowetz A, Thomas C, Horn F, Reiche K, Kreux M, Josefsson A, Tandefekt DG, Hugosson J, Huisman H, Hofmacher T, Lindgren P, Andersson E, Fridhammar A, Vizcaya D, Verholen F, Zong J, Butler-Ransohoff JE, Williamson T, Chandrawansa K, Dlamini D, waldeck R, Molnar M, Bruno A, Herrera R, Jiang S, Nevedomskaya E, Fatoba S, Constantinovici N, Maass M, Torremante P, Voss M, Devecseri Z, Cuperus G, Abott T, Dau C, Papineni K, Wang-Silvanto J, Hass S, Snijder R, Doye V, Wang X, Garnham A, Lambrecht M, Wolfinger R, Rogiers S, Servan A, Lefresne F, Caseriego J, Samir M, Lawson J, Pacoe K, Robinson P, Jaton B, Bakkard D, Turunen H, Kilkku O, Pohjanjousi P, Voima O, Nevalaita L, Reich C, Araujo S, Longden-Chapman E, Burke D, Agapow P, Derkits S, Licour M, McCrea C, Payne S, Yong A, Thompson L, Lujan F, Bussmann M, Köhler I. How well do polygenic risk scores identify men at high risk for prostate cancer? Systematic review and meta-analysis. Clin Genitourin Cancer 2022; 21:316.e1-316.e11. [PMID: 36243664 DOI: 10.1016/j.clgc.2022.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Revised: 09/01/2022] [Accepted: 09/06/2022] [Indexed: 11/27/2022]
Abstract
OBJECTIVES Genome-wide association studies have revealed over 200 genetic susceptibility loci for prostate cancer (PCa). By combining them, polygenic risk scores (PRS) can be generated to predict risk of PCa. We summarize the published evidence and conduct meta-analyses of PRS as a predictor of PCa risk in Caucasian men. PATIENTS AND METHODS Data were extracted from 59 studies, with 16 studies including 17 separate analyses used in the main meta-analysis with a total of 20,786 cases and 69,106 controls identified through a systematic search of ten databases. Random effects meta-analysis was used to obtain pooled estimates of area under the receiver-operating characteristic curve (AUC). Meta-regression was used to assess the impact of number of single-nucleotide polymorphisms (SNPs) incorporated in PRS on AUC. Heterogeneity is expressed as I2 scores. Publication bias was evaluated using funnel plots and Egger tests. RESULTS The ability of PRS to identify men with PCa was modest (pooled AUC 0.63, 95% CI 0.62-0.64) with moderate consistency (I2 64%). Combining PRS with clinical variables increased the pooled AUC to 0.74 (0.68-0.81). Meta-regression showed only negligible increase in AUC for adding incremental SNPs. Despite moderate heterogeneity, publication bias was not evident. CONCLUSION Typically, PRS accuracy is comparable to PSA or family history with a pooled AUC value 0.63 indicating mediocre performance for PRS alone.
Collapse
|
5
|
Lievens Y, Boesmans L, Engels H, Geets X, Jansen N, Janssens S, Lambrecht M, Remouchamps V, Roosens S, Stellamans K, Verellen D, Weltens C, Weytjens R, Van Damme N. OC-0505 Coverage with evidence development: generating real-life evidence on SBRT in Belgium. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02605-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
De Roeck L, Blommaert J, Defraene G, Sleurs C, Vandenbussche L, Lambrecht M. PO-1133 Comparative planning study (IMPT vs VMAT) on sparing OARs important for neurocognition in gliomas. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03097-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Lievens Y, Lambrecht M, Boesmans L, Engels H, Geets X, Janssens S, Moretti L, Remouchamps V, Roosens S, Van Damme N. OC-0752 SBRT for lung cancer and lung metastases: prospective national registration project in Belgium. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02658-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Lambrecht M. SP-0847 Follow-up after irradiation of primary brain tumours. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)04041-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Rancati T, Gioscio E, Cicchetti A, Rosenstein B, Seibold P, Avuzzi B, Azria D, Choudhury A, De Ruysscher D, Dunning A, Elliott R, Kerns S, Lambrecht M, Sperk E, Symonds P, Talbot C, Vega A, Veldeman L, Valdagni R, Webb A, Chang-Claude J, West C. MO-0557 Estimates of α/β ratios for individual late urinary toxicity endpoints: analysis of a cohort trial. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02391-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Cicchetti A, La Rocca E, De Santis M, Seibold P, Azria D, De Ruysscher D, Valdagni R, Dunning A, Elliot R, Gutiérrez-Enríquez S, Lambrecht M, Sperk E, Rancati T, Rattay T, Rosenstein B, Talbot C, Vega A, Veldeman L, Webb A, Chang-Claude J, West C. MO-0801 Machine learning based models of radiotherapy-induced skin induration for breast cancer patients. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02437-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Verfaillie S, Van de Velde AS, Berkovic P, Dooms C, Nackaerts K, Vansteenkiste J, Lambrecht M, Wauters E. 121P Treatment of unresectable stage III NSCLC: Real-world study and literature review. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
12
|
Oldenburger E, Cappelle S, Wildiers H, Punie K, Daisne JF, Lambrecht M. Solitary pituitary metastasis from HER2-positive breast cancer treated with stereotactic radiotherapy – a case report. Current Problems in Cancer: Case Reports 2021. [DOI: 10.1016/j.cpccr.2021.100081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
13
|
Vandewinckele L, Willems S, Lambrecht M, Maes F, Crijns W. PD-0819 Dose mimicking by deep learning based fluence prediction: one model for different class solutions. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07098-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Prades J, Borras J, Bibault J, Grau C, Jereczek-Fossa B, Lambrecht M, Slotman B, Troost E, Lievens Y. PO-1493 Opening the angle: the role played by National Societies for Radiation Oncology during the COVID-19. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07944-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Cooke S, De Ruysscher D, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman E, Van Diessen J, Sikorska K, Lalezari F, Sonke J, Belderbos J. OA02.05 Local, Regional and Pulmonary Failures in the Randomised PET-Boost Trial for NSCLC Patients. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.278] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Delombaerde L, Depuydt T, Berkovic P, Lambrecht M. PO-1617: PO-1617 Feasibility of spirometer-guided single breath-hold kV-CBCTs on Halcyon in lung cancer patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01635-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Charlier F, Lievens Y, Geets X, Remouchanps V, Hortobágyi E, Lambrecht M, Moretti L. Standardisation du volume cible anatomoclinique ganglionnaire médiastinal pour les cancers bronchiques non à petites cellules de stade III : résultats d’un dummy run national en deux phases. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel R, Vansteenkiste J, De Ruysscher D. Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz259] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Belderbos J, de Ruysscher D, DeJaeger K, Lievens Y, Koppe F, Lambrecht M, Dieleman E, Jaspers J, Van Meerbeeck J, Ubbels F, Kwint M, Muller P, Kuenen M, Deprez S, de Ruiter M, van Tinteren H, Schagen S. The Incidence and Location of Brain Metastases Following HA-PCI Compared with Standard PCI in Small Cell Lung Cancer (SCLC) : A Phase III Trial. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.450] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
20
|
Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer 2019; 133:83-87. [PMID: 31200833 DOI: 10.1016/j.lungcan.2019.05.001] [Citation(s) in RCA: 100] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2019] [Revised: 04/25/2019] [Accepted: 05/03/2019] [Indexed: 12/13/2022]
Abstract
OBJECTIVES Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in pre-clinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical trial. MATERIAL AND METHODS NICOLAS is a phase-II trial evaluating the safety and efficacy of nivolumab combined with CRT in stage III NSCLC. Patients received 3 cycles of platinum-based chemotherapy and concurrent RT (66 Gy/33fractions). Nivolumab started concurrently with RT. The primary endpoint was 6-month post-RT rate of grade-≥3-pneumonitis. A formal interim safety analysis (IA) was scheduled when the first 21 patients reached 3 months follow-up post-RT. An early positive safety conclusion would be reached at IA if there were no grade ≥3-pneumonitis in those patients. Efficacy evaluation was planned provided the safety conclusion was reached. RESULTS AND CONCLUSION As of 13 December 2018, 82 patients were recruited with median follow-up of 13.4 months. The most frequent adverse events (AEs) were anaemia, fatigue and pneumonitis. No unexpected AEs or increased toxicities were observed. For the first 21 patients, no grade-≥3-pneumonitis was observed by the end of the 3-month post-RT follow-up period. The early safety IA provides evidence that the addition of nivolumab to concurrent CRT is safe and tolerable regarding the 6-month rate of pneumonitis grade ≥3 at the one-sided significance level of 5%. Following that, the 1-year progression-free survival will be evaluated in an expanded patient cohort. NICOLAS trial creates the opportunity for assessing the activity of the combination of checkpoint with concurrent CRT in larger prospective trials for locally advanced NSCLC.
Collapse
Affiliation(s)
- S Peters
- Centre Hospitalier Universitaire Vaudois (CHUV), Département d'Oncologie, Lausanne, Switzerland
| | - E Felip
- Vall d'Hebron University Hospital, Institute of Oncology (VHIO), Barcelona, Spain
| | - U Dafni
- Frontier Science Foundation-Hellas & National and Kapodistrian University of Athens, Greece
| | - C Belka
- Department of Radiation Oncology and DZL Munich, University Hospital, LMU Munich, Germany
| | - M Guckenberger
- University Hospital Zurich, Department for Radiation Oncology, University of Zurich, Switzerland
| | - A Irigoyen
- Hospital Virgen De La Salud, Department of Medical Oncology, Toledo, Spain
| | - E Nadal
- Catalan Institute of Oncology, Department of Medical Oncology, IDIBELL L'Hospitalet, Barcelona, Spain
| | - A Becker
- Amsterdam University Medical Center, Department of Respiratory Diseases, Amsterdam, the Netherlands
| | - H Vees
- Clinic Hirslanden, Radiation Oncology, Zürich, Switzerland
| | - M Pless
- Cantonal Hospital Winterthur, Medical Oncology, Winterthur, Switzerland
| | - A Martinez-Marti
- Vall d'Hebron University Hospital, Institute of Oncology (VHIO), Barcelona, Spain
| | - A Tufman
- Ludwig Maximilian University of Munich (LMU), Medizinische Klinik and Poliklinik V, German Center for Lung Research, Munich, Germany
| | - M Lambrecht
- University Hospitals Gasthuisberg, Department of Radiotherapy-Oncology, Leuven, Belgium
| | - N Andratschke
- University Hospital Zurich, Department for Radiation Oncology, University of Zurich, Switzerland
| | - A C Piguet
- European Thoracic Oncology Platform (ETOP), Bern, Switzerland
| | - M Kassapian
- Frontier Science Foundation-Hellas, Athens, Greece
| | | | | | - R A Stahel
- University Hospital Zurich, Department of Haematology and Oncology, Switzerland
| | - J Vansteenkiste
- University Hospitals Gasthuisberg, Department of Respiratory Diseases, Leuven, Belgium
| | - D De Ruysscher
- Maastro Clinic, Department of Radiation Oncology Maastricht, the Netherlands.
| |
Collapse
|
21
|
Adebahr S, Liu Y, Colette S, Faivre-Finn C, Ahmad S, Ahmed M, Belderbos J, Andratschke N, Franks K, Geets X, Guckenberger M, Konopa K, Lambrecht M, Lewitzki V, Lievens Y, Pourel N, De Ruysscher D, Dziadziuszko R, Fortpied C, McDonald F, Peulen H, Grosu A, Hurkmans C, Le Pechoux C, Nestle U. OC-0061 EORTC 22113-8113 Lungtech trial on SBRT of central lung tumors. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30481-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Thomas M, Defraene G, Lambrecht M, Deng W, Moons J, Nafteux P, Lin S, Haustermans K. PV-0622 NCTP model for postoperative pulmonary complications after trimodality therapy in esophageal cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31042-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Lambrecht M, Clement E, Sonke J, Nestle U, Adebahr S, Guckenberger M, Weber D, Hurkmans C. PV-0200: Benchmark Case results from the EORTC Lungtech trial of SBRT for patients with centrally NSCLC. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30510-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Defraene G, Arredouani S, Van Elmpt W, Lambrecht M, De Ruysscher D. PV-0317: A NTCP model for mortality after chemo-RT for lung cancer including mean heart dose and GTV. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30627-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
25
|
Lambrecht M, Sonke J, Nestle U, Peulen H, Weber D, Verheij M, Hurkmans C. PO-0967: Quality assurance of 4DCT in the EORTC Lungtech trial on SBRT for patients with NSCLC. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31277-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Lambrecht M, Sonke J, Nestle U, Guckenberger M, Peulen H, Weber D, Verheij M, Hurkmans C. EP-2209: Results of a multicentre dosimetry audit using a respiratory phantom within the EORTC Lungtech trial. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32518-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
27
|
Decaluwe H, Moons J, De Wever W, Deroose C, Stanzi A, Depypere L, Nackaerts K, Coolen J, Lambrecht M, De Ruysscher D, Vansteenkiste J, Van Raemdonck D, De Leyn P, Dooms C. P1.13-007 Is Central Lung Tumor Location Really Predictive for Occult Mediastinal Nodal Disease in (Suspected) NSCLC Staged cN0 on PET-CT? J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Decaluwe H, Moons J, Lambrecht M, De Wever W, Coolen J, Deroose C, Depypere L, Van Raemdonck D, De Leyn P, Dooms C. P-106SURVIVAL ANALYSIS IN PATIENTS WITH cSTAGE-I SUSPECTED NON-SMALL CELL LUNG CANCER REFERRED TO SURGERY BUT WHO WERE ALSO CANDIDATES FOR STEREOTACTIC BODY RADIATION THERAPY. Interact Cardiovasc Thorac Surg 2017. [DOI: 10.1093/icvts/ivx280.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
29
|
Lambrecht M, Sonke J, Verheij M, Hurkmans C. OC-0539: A multicentre QA study on 4DCT and IMRT/VMAT techniques for lung SBRT using a respiratory phantom. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30979-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Lambrecht M, Ortega Marin K, La Fontaine M, Sonke J, Boellaard R, Verheij M, Hurkmans C. EP-1682: Comparison of SUV based on different ROIs and VOIs definitions: a multi-center 4D phantom study. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)32214-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
31
|
Lambrecht M, Hurkmans C. 28. A multicentre QA study on 4DCT and IMRT/VMAT techniques for lung stereotactic treatments using the 008A CIRS 4D phantom. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.11.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U. Stereotactic body radiotherapy for central lung tumours: Author reply. Br J Radiol 2015; 88:20150532. [PMID: 26151618 PMCID: PMC4743584 DOI: 10.1259/bjr.20150532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 07/06/2015] [Indexed: 11/05/2022] Open
Affiliation(s)
- S Adebahr
- Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Partner Site, Freiburg, Germany
| | | | - E Shash
- EORTC Headquarters, Brussels, Belgium
| | - M Lambrecht
- Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands
| | - C Le Pechoux
- Department of Radiation Oncoiogy, Gustave Roussy, Paris Sud University, Villejuif, France
| | - C Faivre-Finn
- Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, UK
| | - D De Ruysscher
- Department of Radiation Oncology, KU Leuven—University of Leuven, University Hospitals Leuven, Leuven, Belgium
| | - H Peulen
- Department of Radiation Oncology, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - J Belderbos
- Department of Radiation Oncology, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - R Dziadziuszko
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
| | - C Fink
- Department of Radiology, Allgemeines Krankenhaus Celle, Celle, Germany
| | - M Guckenberger
- Department of Radiation Oncology, University of Zurich, Zurich, Switzerland
| | - C Hurkmans
- Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands
| | - U Nestle
- Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Partner Site, Freiburg, Germany
| |
Collapse
|
33
|
Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; 88:20150036. [PMID: 25873481 PMCID: PMC4628529 DOI: 10.1259/bjr.20150036] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Revised: 04/02/2015] [Accepted: 04/13/2015] [Indexed: 12/16/2022] Open
Abstract
Evidence supports stereotactic body radiotherapy (SBRT) as a curative treatment option for inoperable early stage non-small-cell lung cancer (NSCLC) resulting in high rates of tumour control and low risk of toxicity. However, promising results are mainly derived from SBRT of peripheral pulmonary lesions, whereas SBRT for the central tumours can lead to severe radiation sequelae owing to the spatial proximity to the serial organs at risk. Robust data on the tolerance of mediastinal structures to high-dose hypofractionated radiation are limited; furthermore, there are many open questions regarding the efficiency, safety and response assessment of SBRT in inoperable, centrally located early stage NSCLC, which are addressed in a prospective multicentre study [sponsored by the European Organization for Research and Treatment of Cancer (EORTC 22113-08113-LungTech)]. In this review, we summarize the current status regarding SBRT for centrally located early stage NSCLC that leads to the rationale of the LungTech trial. Outline and some essential features of the study with focus on a summary of current experiences in dose/fraction-toxicity coherences after SBRT to the mediastinal structures that lead to LungTech normal tissue constraints are provided.
Collapse
Affiliation(s)
- S Adebahr
- Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Partner Site Freiburg, Germany
| | | | - E Shash
- EORTC Headquarters, Brussels, Belgium
| | - M Lambrecht
- Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands
| | - C Le Pechoux
- Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
| | - C Faivre-Finn
- Institute of Cancer Sciences, Radiotherapy Related Research, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK
| | - D De Ruysscher
- KU Leuven–University of Leuven, University Hospitals Leuven, Department of Radiation Oncology, Leuven, Belgium
| | - H Peulen
- Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - J Belderbos
- Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - R Dziadziuszko
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
| | - C Fink
- Department of Radiology, Allgemeines Krankenhaus Celle, Celle, Germany
| | - M Guckenberger
- Department of Radiation Oncology, University of Zurich, Zurich, Switzerland
| | - C Hurkmans
- Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands
| | - U Nestle
- Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Partner Site Freiburg, Germany
| |
Collapse
|
34
|
Nevens D, Lambrecht M, De Keyzer F, Vandecaveye V, Hermans B, Nuyts S. PD-0418: The use of diffusion weighted MRI in the prediction of volumetric changes during radiotherapy. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40414-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Nuyts S, Lambrecht M, Duprez F, Daisne J, Van den Weyngaert D, Platteaux N, Geussens Y, Voordeckers M, Madani I. OC-0141: Reduction of the dose to the elective CTV in HNSCC using IMRT. Dosimetrical analysis and effect on acute toxicity. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)32447-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Nevens D, Lambrecht M, Hermans R, De Keyzer F, Vandecaveye V, Nuyts S. PD-024: The use of Sequential Diffusion Weighted MRI in the Early Prediction of Volumetric Changes During Radiotherapy. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)34643-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
37
|
Lambrecht M, Graves Y, Gautier Q, Tian Z, Kim G, Uribe-Sanchez A, Jia X, Jiang S. WE-G-BRCD-01: A Procedure for Efficient Large-Scale Retrospective Clinical Studies for Online Adaptive Radiotherapy. Med Phys 2012; 39:3964. [DOI: 10.1118/1.4736178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
38
|
Graves Y, Zhen X, Kim G, Gautier Q, Tian Z, Cervino L, Lambrecht M, Jia X, Jiang S. SU-E-T-340: Estimation of the Delivered Fractional and Accumulative Patient Dose in IMRT and VMAT. Med Phys 2012. [DOI: 10.1118/1.4735427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
39
|
Lambrecht M, Nevens D, Nuyts S. EP-1185 THE EFFECT OF IMRT ON OUTCOME AND TOXICITY COMPARED TO 3DCRT. A MONO-CENTRIC, RETROSPECTIVE ANALYSIS. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71518-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
40
|
Lambrecht M, Vandecaveye V, van Limbergen E, Roebben I, de Keyzer F, Hermans R, Nuyts S. 836 poster FUNCTIONAL MR IMAGING IN PATIENTS WITH OROPHARYNGEAL CANCER AND THE RELATION TO HPV. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70958-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
Lambrecht M, Vandecaveye V, Van Limbergen E, Hauben E, Dok R, Roebben I, De Keyzer F, Hermans R, Nuyts S. The prognostic value of pretherapeutic diffusion-weighted MRI in oropharyngeal carcinoma treated with (chemo-)radiotherapy. Cancer Imaging 2011. [DOI: 10.1102/1470-7330.2011.9056] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
42
|
van Stiphout R, Janssen M, van den Bogaard J, Leccisotti L, Coco C, Lambrecht M, Lammering G, Haustermans K, Valentini V, Lambin P. 6047 Development of nomograms for prediction of pathologic complete response in locally advanced rectum cancer: a multicentric study using PET before, during and after neoadjuvant chemoradiotherapy. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71142-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
43
|
Delwiche E, Mertens I, Lambrecht M, Roels S, Verstraete J, Van Clemen F, Van Limbergen E, Haustermans K. ADEQUATE PATIENT POSITIONING AND REDUCTION OF IRRADIATED SMALL BOWEL VOLUME IN PELVIC RADIOTHERAPY: A COMPARISON OF TWO BELLY BOARD DEVICES. Radiother Oncol 2009. [DOI: 10.1016/s0167-8140(12)72828-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
van Stiphout R, Lambrecht M, Janssen M, Slagmolen P, Lammering G, Buijsen J, Haustermans K, Lambin P. THE VALUE OF PREDICTING PATHOLOGICAL COMPLETE RESPONSE IN RECTAL CANCER WITH FDG-PET DURING RADIOCHEMOTHERAPY. Radiother Oncol 2009. [DOI: 10.1016/s0167-8140(12)72911-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
45
|
Jardin M, Almazouzi A, Lambrecht M, Rempel A, Nagai Y, van Walle E. Digital positron lifetime spectrometer for measurements of radioactive materials. ACTA ACUST UNITED AC 2007. [DOI: 10.1002/pssc.200675816] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
46
|
|
47
|
Lambrecht M. [Not Available]. Wiss Beitr Martin Luther Univ Halle Wittenberg 2001; 5-R80:63-70. [PMID: 11628984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
48
|
Lambrecht M. [Not Available]. Orvostort Kozl 2001; 89-91:233-9. [PMID: 11628719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
49
|
Lambrecht M. [Not Available]. Orvostort Kozl 2001; 29:9-21. [PMID: 11634096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
50
|
Dosselaere F, Lambrecht M, Vanderleyden J. Isolation and sequence analysis of the trpBA gene cluster, encoding tryptophan synthase, from Azospirillum brasilense. DNA Seq 2001; 11:287-93. [PMID: 11092742 DOI: 10.3109/10425170009033245] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The trpBA gene cluster of Azospirillum brasilense Sp7 was isolated by complementation of an Escherichia coli trpBA mutant. Both genes code for the two subunits of tryptophan synthase, which catalyzes the last step in tryptophan biosynthesis. No structural features indicating transcriptional regulation could be identified. Upstream of the trpBA cluster an open reading frame encoding a putative periplasmic binding protein, involved in amino acid transport, was identified. Analysis of the downstream region of the trpBA cluster revealed the presence of a putative open reading frame encoding a subunit of the acetyl-coenzyme A carboxylase carboxyl transferase complex.
Collapse
Affiliation(s)
- F Dosselaere
- F.A. Janssens Laboratory of Genetics, K. U. Leuven, Heverlee, Belgium
| | | | | |
Collapse
|